24 completed, 3 terminated, 1 active not recruiting. 13 Phase 2, 12 Phase 1, 1 Phase 3.
By phase and status
Follow Ono Pharma USA Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
Non-Small Cell Lung Cancer | | Active not recruiting | Bristol-Myers Squibb | 525 | 2020-12-15 | 2026-06-02 |
Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread
Cancer of Head and Neck, Cancer of the Head | | Completed | Bristol-Myers Squibb | 262 | 2018-02-14 | 2022-02-10 |
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
Non-Interventional - Kidney Cancer, Renal Cancer | | Completed | Bristol-Myers Squibb | 212 | 2018-02-14 | 2022-10-20 |
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
ONO-2952, Placebo comparator - Irritable Bowel Syndrome (IBS) | Phase 2 | Terminated | Ono Pharma USA Inc | 39 | 2013-06-01 | 2016-02-25 |
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
ONO-2952, ONO-2952 Matching Placebo - Irritable Bowel Syndrome (IBS) | Phase 2 | Completed | Ono Pharma USA Inc | 200 | 2013-04-01 | 2016-04-15 |
An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment
ONO-2745 /CNS 7056 - Hepatic Impairment, Healthy | Phase 1 | Completed | Ono Pharma USA Inc | 20 | 2013-02-01 | 2013-12-03 |
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
ONO-9054, Placebo - Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG) | Phase 1 | Completed | Ono Pharma USA Inc | 60 | 2012-08-01 | 2013-06-03 |
ONO-2952 Single-dose PET Study in Healthy Adult Subjects
ONO-2952 - Healthy Adult Subjects | Phase 1 | Completed | Ono Pharma USA Inc | 16 | 2012-08-01 | 2013-06-03 |
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
ONO-6950, Placebo, Montelukast - Asthma | Phase 2 | Completed | Ono Pharma USA Inc | 25 | 2012-06-01 | 2013-04-30 |
A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients
ONO-6950, Montelukast, Placebo - Asthma | Phase 2 | Completed | Ono Pharma USA Inc | 59 | 2012-03-01 | 2014-02-14 |
Single Dose Escalation Study of ONO-9054 in Healthy Volunteers
ONO-9054 - Healthy Adult Subjects | Phase 1 | Completed | Ono Pharma USA Inc | 48 | 2012-01-01 | 2012-06-14 |
Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
ONO-2952, ONO-2952 Matching Placebo - Healthy | Phase 1 | Completed | Ono Pharma USA Inc | 36 | 2011-12-01 | 2012-08-01 |
Phase I Biomarker Study (BMS-936558)
BMS-936558 (Anti-PD-1) - Renal Cell Carcinoma | Phase 1 | Completed | Bristol-Myers Squibb | 119 | 2011-09-23 | 2021-10-28 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects
ONO-6950 - Healthy Adult Subjects | Phase 1 | Completed | Ono Pharma USA Inc | 24 | 2011-07-01 | 2012-06-14 |
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
nivolumab - Renal Cell Carcinoma | Phase 2 | Completed | Bristol-Myers Squibb | 168 | 2011-05-31 | 2022-05-12 |
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
ONO-7746 - Chemotherapy-Induced Thrombocytopenia | Phase 1 | Terminated | Ono Pharma USA Inc | 17 | 2011-05-01 | 2014-04-01 |
Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
ONO-2952, Placebo - Healthy Adult Subjects | Phase 1 | Completed | Ono Pharma USA Inc | 48 | 2011-05-01 | 2012-06-13 |
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects
ONO-6950 - Healthy Adult Subjects | Phase 1 | Completed | Ono Pharma USA Inc | 56 | 2011-01-01 | 2012-06-14 |
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
ONO-4641, ONO-4641 placebo - Multiple Sclerosis | Phase 2 | Completed | Ono Pharma USA Inc | 407 | 2010-03-01 | 2013-12-25 |
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
BMS-936558 (MDX1106-04), Ipilimumab - Malignant Melanoma | Phase 1 | Completed | Bristol-Myers Squibb | 127 | 2009-12-14 | 2026-08-03 |
Showing 20 of 28. Sign in to see all of them.
Conditions studied
Asthma (2) · Carcinoma, Renal Cell (2) · Diabetes Mellitus, Type 2 (2) · Irritable Bowel Syndrome (2) · Osteoporosis (2) · Alzheimer Disease (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Carcinoma, Non-Small-Cell Lung (1) · Coitus (1) · Depressive Disorder, Major (1) · Eye Diseases (1) · Glaucoma (1) · Glaucoma, Open-Angle (1) · Head and Neck Neoplasms (1)
Interventions
ONO-2952 (5) · gemilukast (4) · Nivolumab (3) · montelukast (2) · propan-2-yl 4-(6-(4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl)-7-hydroxyoctahydro-2H-cyclopenta(b)oxepin-3-yl)butanoate (2) · Ipilimumab (1) · ONO-5334 (1) · ONO2506 (1) · YM 529 (1) · ceralifimod (1) · landiolol (1) · remimazolam (1)
Countries
United States (20) · Japan (6) · Canada (5) · Russia (2) · Spain (2) · Belgium (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1)
Top investigators
Project Leader, Development Planning (2) · Bryan Due, Ph.D. (1) · Joseph G Bisaha, Ph.D. (1) · Katsutoshi Hatakeyama, M.S. (1) · Tomohiro Kuwayama (1)
Results publications
PMID 26249232, PMID 21917625, PMID 23724867, PMID 23873670, PMID 25452452, PMID 26453641, PMID 26720443, PMID 26771550, PMID 27243803, PMID 27444660, PMID 27910150, PMID 29040030, PMID 32371459, PMID 33219460, PMID 33658305, PMID 33830342, PMID 34246461, PMID 39504507